Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020137076 - METHOD FOR PREDICTING SUSCEPTIBILITY OF CANCER TO PARP INHIBITORS, AND METHOD FOR DETECTING CANCER HAVING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY

Publication Number WO/2020/137076
Publication Date 02.07.2020
International Application No. PCT/JP2019/039415
International Filing Date 04.10.2019
IPC
C12Q 1/6869 2018.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
A61K 45/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6869Methods for sequencing
Applicants
  • 国立大学法人 東京大学 THE UNIVERSITY OF TOKYO [JP]/[JP]
  • 学校法人埼玉医科大学 SAITAMA MEDICAL UNIVERSITY [JP]/[JP]
Inventors
  • 織田 克利 ODA Katsutoshi
  • 油谷 浩幸 ABURATANI Hiroyuki
  • 山本 尚吾 YAMAMOTO Shogo
  • 長谷川 幸清 HASEGAWA Kosei
Agents
  • 横田 修孝 YOKOTA Nobutaka
  • 榎 保孝 ENOKI Yasutaka
  • 大森 未知子 OMORI Michiko
  • 赤羽 桃子 AKABA Momoko
Priority Data
2018-24861928.12.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) METHOD FOR PREDICTING SUSCEPTIBILITY OF CANCER TO PARP INHIBITORS, AND METHOD FOR DETECTING CANCER HAVING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY
(FR) PROCÉDÉ DE PRÉDICTION DE LA SENSIBILITÉ D'UN CANCER CIBLE AUX INHIBITEURS DE LA PARP, ET PROCÉDÉ DE DÉTECTION DU CANCER PRÉSENTANT UNE DÉFICIENCE DE RÉPARATION DE RECOMBINAISON HOMOLOGUE
(JA) PARP阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法
Abstract
(EN)
The purpose of the present invention is to provide a method for predicting the susceptibility of a target cancer to PARP inhibitors. The present invention provides a method for predicting the susceptibility of a cancer to PARP inhibitors. The method includes a step for creating a mutation catalog by performing a sequence analysis on nucleic acid samples obtained from cancer cells. The presence of a cancer that is susceptible to PARP inhibitors is indicated by the contribution of BRCA signatures to the mutation catalog being greater than the contribution of Age signatures to the mutation catalog and by an absence of cyclin E1 amplification.
(FR)
La présente invention a pour objet une méthode de prédiction de la sensibilité d'un cancer cible aux inhibiteurs de la PARP. La présente invention a pour but de fournir une méthode de prédiction de la sensibilité d'un cancer aux inhibiteurs de la PARP. Le procédé comprend une étape de création d'un catalogue de mutation par réalisation d'une analyse de séquence sur des échantillons d'acide nucléique obtenus à partir de cellules cancéreuses. La présence d'un cancer étant sensible aux inhibiteurs de la PARP est indiquée par la contribution des signatures BRCA au catalogue de mutations, cette dernière étant supérieure à la contribution des signatures liées à l'âge au catalogue de mutations et par une absence d'amplification de cycline E1.
(JA)
本発明はPARP阻害剤に対する対象の癌の感受性の予測方法の提供を目的とする。本発明によれば、PARP阻害剤に対する癌の感受性を予測する方法であって、癌細胞から得られた核酸試料について配列解析を実施して変異カタログを作成する工程を含んでなり、変異カタログに対するBRCAシグネチャーの寄与が、変異カタログに対するAgeシグネチャーの寄与を上回り、かつサイクリンE1増幅が不存在であることが、PARP阻害剤に対して感受性を有する癌の存在を示す予測方法が提供される。
Also published as
JP2020562373
Latest bibliographic data on file with the International Bureau